PharmaDossierIndependent biopharma information, guidance, and source-cited analysis.

Topic

Accelerated Approval

Surrogate endpoints, confirmatory trials, withdrawal risk, payer skepticism, and commercial exposure.

1 article·Lives underPipeline Policy·Last updated 2026-05-13

Pipeline· May 7, 2026 · 4 min read

Accelerated approval creates commercial risk even before confirmatory failure

Accelerated approval can speed access, but commercial teams still need a plan for confirmatory trials, label uncertainty, payer skepticism, and withdrawal risk.

By Ran Chen#Accelerated Approval #FDA Approval #Clinical Evidence